ATS 2022
Does omalizumab therapy for patients with moderate to severe allergic asthma affect these patients’ use of antitussives?
News
This is the first OTC formulation for Nasonex and is expected to be available later this year.
AAAAI 2022
Does the allergic status of patients with asthma affect asthma exacerbation rates and outcomes following COVID-19?
AAAAI 2022
The VOYAGE trial assessed the effect of dupilumab on asthma control in children with type 2 inflammatory asthma phenotype.
News
Ryaltris is a metered, fixed-dose nasal spray that delivers 665mcg of olopatadine hydrochloride and 25mcg of mometasone furoate in each spray.
News
By targeting these regions of the nasal cavity, the device is able provide symptom relief for patients with chronic rhinitis.
ACAAI 2021
Researchers examined health disparities in the duration of asthma exacerbations in patients post-COVID-19.
ACAAI 2021
A prospective, single-center study examined the use of allergen immunotherapy for alleviating the burden of allergic rhinitis.
AAO-HNS 2021
Study authors evaluated the impact on compliance and SNOT-20 scores in patients with allergic rhinitis using a novel sinus nasal rinse device.
AAO-HNS 2021
The authors utilized medical and pharmacy claims obtained from the Optum Clinformatics Data Mart Database.